XML 67 R30.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Revenue Recognition (Tables)
 12 Months Ended
Dec. 31, 2019
Revenue from Contract with Customer [Abstract]  
Contract with Customer, Asset and Liability The following table summarizes the values of contract assets, capitalized commissions and contract liabilities as of December 31, 2019 and December 31, 2018 (in thousands):
December 31, 2019December 31, 2018
Current pharma contract assets (1)
$1,000  $86  
Long-term pharma contract assets (2)
153  268  
Total pharma contract assets$1,153  $354  
Current pharma capitalized commissions (1)
$133  $271  
Long-term pharma capitalized commissions (2)
798  650  
Total pharma capitalized commissions$931  $921  
Current pharma contract liabilities$1,610  $927  
Long-term pharma contract liabilities (3)
1,171  1,652  
Total pharma contract liabilities$2,781  $2,579  

(1) Current pharma contract assets and current pharma capitalized commissions are classified as “Other current assets” on the Consolidated Balance Sheets.
(2) Long-term pharma contract assets and long-term pharma capitalized commissions are classified as “Other assets” on the Consolidated Balance Sheets.
(3) Long-term pharma contract liabilities are classified as “Other long-term liabilities” on the Consolidated Balance Sheets.
Disaggregation of Revenue The following table details the disaggregation of revenue for both the Clinical and Pharma Services Segments (in thousands):
December 31, 2019December 31, 2018December 31, 2017
Clinical Services:
    Client direct billing$212,703  $164,888  $147,726  
    Commercial Insurance83,107  40,360  35,473  
    Medicare and Medicaid64,745  35,566  29,493  
    Self-Pay606  1,059  405  
Total Clinical Services361,161  241,873  213,097  
Pharma Services:47,669  34,868  27,154  
Total Revenue$408,830  $276,741  $240,251